Transplantation of Modified Monocytes

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a medical therapy using antigen-loaded antigen-presenting cells (APCs), like monocytes, that are engineered outside the body to present specific antigens (for example, tetanus toxoid) and then transplanted into patients who have already been immunized against those antigens. The approach is designed to trigger a targeted immune response that promotes the growth of new collateral blood vessels, particularly in patients suffering from vascular occlusive diseases (e.g., coronary artery disease, peripheral artery disease) where conventional treatments may not be effective or possible.

Use CasesContent extracted from patent full text and abstract with AI.

• Therapeutic treatment of patients with coronary artery disease, especially those not eligible for traditional interventions like stenting or bypass surgery.
• Treatment of peripheral artery disease to restore blood flow to limbs and reduce ischemia.
• Supporting blood vessel growth after surgical or radiation-induced arterial damage.
• Potential use in animal healthcare for similar occlusive vascular conditions in mammals.
• Complementary therapy to improve outcomes in patients who have recurring artery blockages (restenosis).

BenefitsContent extracted from patent full text and abstract with AI.

• Enables targeted and robust growth of collateral blood vessels (arteriogenesis) using the body's immune system.
• Reduces reliance on stem or progenitor cell transplantation, thus lowering ethical and safety concerns (e.g., tumor formation, immune incompatibility).
• Minimizes risk of disease transmission by using patient's own (autologous) or genetically identical (syngeneic) cells.
• Can be tailored to use widely-known antigens like tetanus toxoid, making patient preparation easier and safer given widespread immunization.
• May lead to better long-term outcomes for patients resistant or unsuitable for conventional vascular treatments.
• Reduces systemic side effects compared to treatments using systemic administration of high-dose cytokines or growth factors.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to antigen-loaded antigen-presenting cells (APC) for use in a therapeutic method for augmenting collateral vessel growth in a subject in need thereof, methods to use said antigen-loaded antigen-presenting cells and pharmaceutical compositions comprising antigen-loaded antigen-presenting cells.